Practice advisory update summary: Patent foramen ovale and secondary stroke prevention: Report of the Guideline Subcommittee of the American Academy of Neurology
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To update the 2016 American Academy of Neurology (AAN) practice advisory for patients with stroke and patent foramen ovale (PFO). METHODS: The guideline panel followed the AAN 2017 guideline development process to systematically review studies published through December 2017 and formulate recommendations. MAJOR RECOMMENDATIONS: In patients being considered for PFO closure, clinicians should ensure that an appropriately thorough evaluation has been performed to rule out alternative mechanisms of stroke (level B). In patients with a higher risk alternative mechanism of stroke identified, clinicians should not routinely recommend PFO closure (level B). Clinicians should counsel patients that having a PFO is common; that it occurs in about 1 in 4 adults in the general population; that it is difficult to determine with certainty whether their PFO caused their stroke; and that PFO closure probably reduces recurrent stroke risk in select patients (level B). In patients younger than 60 years with a PFO and embolic-appearing infarct and no other mechanism of stroke identified, clinicians may recommend closure following a discussion of potential benefits (absolute recurrent stroke risk reduction of 3.4% at 5 years) and risks (periprocedural complication rate of 3.9% and increased absolute rate of non-periprocedural atrial fibrillation of 0.33% per year) (level C). In patients who opt to receive medical therapy alone without PFO closure, clinicians may recommend an antiplatelet medication such as aspirin or anticoagulation (level C).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kernan, W. N., Ovbiagele, B., Black, H. R., Bravata, D. M., Chimowitz, M. I., Ezekowitz, M. D., Fang, M. C., Fisher, M., Furie, K. L., Heck, D. V., et al. (2014) · Stroke · doi:10.1161/str.0000000000000024 · Cited by 5,170 · cited 1×
“All patients with previous stroke should be treated with an antithrombotic medication indefinitely if there is no bleeding contraindication, regardless of whether a PFO is present or if it is closed.(20) However, specific antithrombotic management for patients with stroke thought to be caused by PFO remains uncertain.”
BackgroundSelf-citationA Re-Evaluation of Random-Effects Meta-Analysis
Higgins, J. P. T., Thompson, S. G., & Spiegelhalter, D. J. (2009) · Journal of the Royal Statistical Society Series A: Statistics in Society · doi:10.1111/j.1467-985x.2008.00552.x · Cited by 2,569
Cryptogenic stroke and underlying atrial fibrillation
Sanna, T., Diener, H.-C., Passman, R. S., Di Lazzaro, V., Bernstein, R. A., Morillo, C. A., Rymer, M. M., Thijs, V., Rogers, T., Beckers, F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313600 · Cited by 2,161
GRADE guidelines: 9. Rating up the quality of evidence
Guyatt, G. H., Oxman, A. D., Sultan, S., Glasziou, P., Akl, E. A., Alonso-Coello, P., Atkins, D., Kunz, R., Brozek, J., Montori, V., et al. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2011.06.004 · Cited by 1,336 · cited 1×
“Development and Evaluation (GRADE) approach.(2,7,8) The panel then derived recommendations using an iterative modified Delphi process after considering the evidence strength, risks and benefits, cost, availability, and patient preference variations.”
MethodEULAR recommendations for the management of antiphospholipid syndrome in adults
Tektonidou, M. G., Andreoli, L., Limper, M., Amoura, Z., Cervera, R., Costedoat-Chalumeau, N., Cuadrado, M. J., Dörner, T., Ferrer-Oliveras, R., Hambly, K., et al. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-215213 · Cited by 1,318
Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism
Weitz, J. I., Lensing, A. W. A., Prins, M. H., Bauersachs, R., Beyer-Westendorf, J., Bounameaux, H., Brighton, T. A., Cohen, A. T., Davidson, B. L., Decousus, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1700518 · Cited by 787
Practical guide to the meta-analysis of rare events
Efthimiou, O. (2018) · Evidence Based Mental Health · doi:10.1136/eb-2018-102911 · Cited by 231
Random-effects meta-analysis: The number of studies matters
Guolo, A., & Varin, C. (2017) · Statistical Methods in Medical Research · doi:10.1177/0962280215583568 · Cited by 203 · cited 1×
“random-effects methods appropriate for studies of rare events have poor precision when the number of studies is low.(4) Thus, for the primary efficacy analysis of recurrent stroke, the panel selected a hybrid approach for meta-analysis(5): a fixed-effect model for hypothesis testing of a treatment effect using inverse…”
MethodCastellucci, L. A., Cameron, C., Le Gal, G., Rodger, M. A., Coyle, D., Wells, P. S., Clifford, T., Gandara, E., Wells, G., & Carrier, M. (2013) · BMJ · doi:10.1136/bmj.f5133 · Cited by 193 · cited 1×
“In addition, there is high-level evidence that anticoagulation is superior to antiplatelet medication for venous thromboembolism.(38,39) The benefit of performing closure in patients being treated with anticoagulation is unclear.”
Background
Cited by
Kleindorfer, D. O., Towfighi, A., Chaturvedi, S., Cockroft, K. M., Gutierrez, J., Lombardi-Hill, D., Kamel, H., Kernan, W. N., Kittner, S. J., Leira, E. C., et al. (2021) · Stroke · doi:10.1161/str.0000000000000375 · Cited by 3,237
Metadata
- Authors
- Messé, S. R., Gronseth, G. S., Kent, D. M., Kizer, J. R., Homma, S., Rosterman, L., Carroll, J. D., Ishida, K., Sangha, N., & Kasner, S. E.
- Venue
- Neurology
- Published
- 2020-05-19
- Volume
- 94
- Issue
- 20
- Pages
- 876-885
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W3021667850
- Cited by
- 205
- References
- 9
- FWCI
- 15.64
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Practice advisory update summary: Patent foramen ovale and secondary stroke prevention: Report of the Guideline Subcommittee of the American Academy of Neurology. https://app.cochat.ai/papers/10.1212/wnl.0000000000009443
- The paper
- Messé, S. R., Gronseth, G. S., Kent, D. M., Kizer, J. R., Homma, S., Rosterman, L., Carroll, J. D., Ishida, K., Sangha, N., & Kasner, S. E. (2020). Practice advisory update summary: Patent foramen ovale and secondary stroke prevention: Report of the Guideline Subcommittee of the American Academy of Neurology. Neurology. https://doi.org/10.1212/wnl.0000000000009443
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.